P N Lara - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

P N Lara

Showing results (21-30 of 25) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 25 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollmentP N Lara, R Higdon, N Lim, et al.

Cancer Treatment and Research Communications|July 13, 2019

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421P N Lara, M Plets, C Tangen, et al.

Cancer Chemotherapy and Pharmacology|August 8, 2001

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium TrialP N Lara, D R Gandara, J Longmate, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 4, 2017

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinomaE Jonasch, E Hasanov, P G Corn, et al.

The Pharmacogenomics Journal|April 9, 2014

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisM M Dias, J-P Pignon, C S Karapetis, et al.

Pageof 3

Search research articles

Showing results (21-30 of 25) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 25 results.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollmentP N Lara, R Higdon, N Lim, et al.

Cancer Treatment and Research Communications|July 13, 2019

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421P N Lara, M Plets, C Tangen, et al.

Cancer Chemotherapy and Pharmacology|August 8, 2001

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium TrialP N Lara, D R Gandara, J Longmate, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 4, 2017

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinomaE Jonasch, E Hasanov, P G Corn, et al.

The Pharmacogenomics Journal|April 9, 2014

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisM M Dias, J-P Pignon, C S Karapetis, et al.

Pageof 3